In this issue:
Efficacy, safety and tolerability of allogeneic CAR NK-cell therapy
Real-world data of anifrolumab
CV risk factors among APS patients
Feasibility of FcRn for cardiac-NL
ANAs and B cell-targeted therapies
Urinary lysine-acetylated peptides and LN diagnosis
Remission and LDA for RA and SLE patients
Solutions for inequitable health outcomes
Prevalence, determinants and outcomes of LLDAS and DORIS
PROMIS for SLE patients with or without FM
Please login below to download this issue (PDF)